SCHEMBL3021382

SCHEMBL3021382

O=S(=O)(c1ccc(Cl)cc1Cl)N1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.48
HSD11B1 P28845 2/20 0.44
POLB P06746 1/20 0.41
LPAR1 Q92633 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
MAPT P10636 3/20 0.40
GAA P10253 1/20 0.40
AR P10275 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013342 0.94 TRPV4 (0.45) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3015465 0.94 TRPV4 (0.45) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3018014 0.94 TRPV4 (0.57) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3008939 0.93 TRPV4 (0.46) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3009094 0.93 TRPV4 (0.47) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3017499 0.92 TRPV4 (0.43) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3008531 0.92 TRPV4 (0.40) TRPV4HSD11B1POLBLPAR1LPAR2
SCHEMBL3015162 0.92 ALDH1A1 (0.44) TRPV4HSD11B1POLBMAPTALDH1A1
SCHEMBL3012911 0.92 ALDH1A1 (0.48) POLBKDM2BMAPTALDH1A1L3MBTL1
SCHEMBL3014572 0.91 ACLY (0.46) TRPV4HSD11B1POLBLPAR1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885HSD11B1 1034/4885POLB 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.